Automated RPR Syphilis Analyzer

The ASI Evolution® is the world’s first and only fully-automated system for nontreponemal RPR Syphilis testing FDA cleared for diagnostic, blood donor screening and cadaveric (Non-heart beating) tissue screening.

Arlington Scientific advocates the use of the RPR test (a nontreponemal test) that detects antibodies formed in response to damaged host cells as the primary way of screening donors. The RPR test indicates if a person has an active infection.

Certifications

CPT Code 86592(Screening)
CPT Code 86593 (Titers)
FDA 510(k) K173376
FDA 510(k) BK170114
FDA 510(k) K182391
FDA 510(k) BK200488
FDA 510(k) K201438
FDA 510(k) BK200539

The Need for Automated RPR Syphilis Testing

STI’s are a significant public health problem in the United States. Every year, an estimated 27 million^1,2new sexually transmitted infections are reported to the Centers for Disease Control and Prevention (CDC) in the United States at a cost of $16 billion in direct medical costs. In 2021, STI’s reached record breaking levels and they continue to increase year to year.³

Among reported STI’s, syphilis continues to climb at an alarming rate. According to a new 2023 report by the CDC, “The United States is currently experiencing a syphilis epidemic, with sustained increases in primary and secondary syphilis.⁴ This increase affects almost every demographic nationally. These new record levels are the highest numbers seen in more than 70 years resulting in a 2,140% increase in syphilis.⁴

Automated Nontreponemal Syphilis Screening

The ASI Evolution Automated (RPR, nontreponemal) Syphilis Analyzer, FDA cleared for diagnostic, blood donor and cadaveric tissue screening, is quickly becoming the standard for automated RPR screening. Now labs can utilize Lab Techs more efficiently and simplify their syphilis screening workload with the ASI Evolution.

Reduce Labor

The ASI Evolution reduces the amount of hands on time required to run an RPR test, freeing up valuable lab resources.

Improve Efficiency

Run 190 tests per hour per analyzer
Load and walk-away
A single operator can run multiple ASI Evolutions simultaneously
Provides the highest endpoint titers for automated RPR testing
Eliminates subjectivity
Positive ID smart rack (available soon) makes loading racks easier and faster

Better Quality

CDC recommended screening test
Arlington Scientific, over 38 years as a Syphilis Authority
Accurate and reproducible results
Data Management (Analyze, Archive, Retrieve)

Lower Costs

Reduced labor expense
Lowest cost syphilis testing reagent
Minimal consumables required
Lower total healthcare cost

Advantages of Traditional Nontreponemal RPR Testing

“The CDC continues to recommend the traditional screening algorithm using a nontreponemal test (e.g., RPR or VDRL), with reactive nontreponemal tests confirmed by treponemal testing.⁴

CDC Traditional versus reverse algorithm chart, side by side comparison.

Competitive matrix Treponemal versus Nontreponemal.

https://www.aafp.org/afp/2010/0115/od1.html#afp20100115od1-b3

Early Detection

A 2015 CDC study determined that nontreponemal tests can detect infection up to 14 days earlier than treponemal tests.

RPR Serological study showing RPR test detecting syphilis fourteen days before nontreponemal tests.

Why Nontreponemal?

The CDC recommends it, doctors prefer it, a majority of labs use it, costs less, better quality, fewer false-positives

The CDC continues to recommend the use of the RPR test as away of determining active infections. In the CDC’s 2023 draft of “Laboratory Recommendations for Syphilis Testing in the United States,” it states that two-thirds of labs or 63.1% of labs continue to use the RPR traditional algorithm. In a cost study, cited in this same draft guidance, it states that treponemal testing is three times more costly than nontreponemal testing based on the CMS (Centers for Medicare and Medicaid Services) fee schedule.

Digital Results

Nonreactive

Reactive results